109. Atypical hemolytic uremic syndrome Clinical trials / Disease details
Clinical trials : 114 / Drugs : 36 - (DrugBank : 7) / Drug target genes : 3 - Drug target pathways : 11
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05684159 (ClinicalTrials.gov) | June 2024 | 4/1/2023 | Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy | A Phase II, Open-Label Study of NM8074 in Patients With Atypical Hemolytic Uremic Syndrome (aHUS) | aHUS - Atypical Hemolytic Uremic Syndrome | Drug: NM8074 | NovelMed Therapeutics | NULL | Not yet recruiting | 18 Years | 65 Years | All | 12 | Phase 2 | NULL |